Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

doi:10.18632/oncotarget.6442

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Oncotarget - 15 Dec 2015

Duquette Mark, Sadow Peter M, Husain Amjad, Sims Jennifer N, Antonello Zeus A, Fischer Andrew H, Song Chen, Castellanos-Rizaldos Elena, Makrigiorgos G Mike, Kurebayashi Junichi, Nose Vania, Van Hummelen Paul, Bronson Roderick T, Vinco Michelle, Giordano Thomas J, Dias-Santagata Dora, Pandolfi Pier Paolo, Nucera Carmelo

Abstract excerpt

BRAF(V600E) mutation exerts an essential oncogenic function in many tumors, including papillary thyroid carcinoma (PTC). Although BRAF(V600E) inhibitors are available, lack of response has been frequently observed. To study the mechanism underlying intrinsic resistance to the mutant BRAF(V600E) selective inhibitor vemurafenib, we established short-term primary cell cultures of human metastatic/recurrent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p16

Share to Heterografts

Share to In Situ Nick-End Labeling

Share to Mice, Inbred NOD

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Thyroid Cancer, Papillary

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 26636651
DOI: 10.18632/oncotarget.6442
PMCID: PMC4767444

Genes

BRAF
MCL1
BCL2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.PMID 26636651Read ↗

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.Semantic proximity Read ↗

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma modelSemantic proximity Read ↗

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.Semantic proximity Read ↗

BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer ProgressionSemantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.Semantic proximity Read ↗

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.